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NUCLEIC ACID ANALOGUE INDUCED 
TRANSCRIPTION OF DOUBLE STRANDED 
DNA 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a continuation-in-part of International 
Application PCT/EP94/03858, ?led Nov. 22, 1994, and 
designating the US. 
The present invention relates to the use of analogues of 
naturally occurring nucleic acids to produce sites for the in 
vitro initiation of transcription of double stranded DNA, to 
the production of RNA transcripts thereby, the ampli?cation 
and/or detection of such transcripts and in vitro diagnostics 
techniques based on the above. 
Analogues of nucleic acids having a peptide or similar 
backbone bearing pendant ligands such as nucleic acid bases 
described in WO 92/20703 (PNA’s) have been shoWn to 
have a number of unusual properties. These include the 
ability to form complexes With double stranded DNA in 
Which tWo strands of PNA complementary in sequence to 
one of the DNA strands hybridise to the DNA displacing the 
other DNA strand. A high level of sequence speci?city has 
been shoWn. 
Transcription of DNA to form a strand of RNA of 
corresponding sequence is initiated in nature by the 
sequence speci?c recognition of a promotor region of the 
double stranded DNA either by RNA polymerase or by 
auxiliary transcription factors. Subsequently, a transcription 
initiation open complex is formed in Which about 12 base 
pairs of the DNA helix is melted so as to expose the bases 
of the template strand for base pairing With the RNA strand 
being synthesised. It has been shoWn that E. coli and phage 
T7 RNA polymerase can utilise synthetic “RNA/DNA 
bubble duplex” complexes containing an RNA/DNA duplex 
and a single stranded DNA D-loop for transcription initia 
tion purposes. 
We have noW discovered that initiation can similarly be 
initiated from a strand displacement complex formed 
betWeen PNA and double stranded DNA. This presents the 
prospect of having a ready and simple Way of preparing 
single stranded transcripts from a double stranded template. 
Generally, techniques for identifying DNA sequences 
depend upon having the DNA in single stranded form. Once 
single stranded, the DNA can be hybridised to a probe of 
complementary sequence and such hybridisation can be 
detected in various Ways. Transcription of RNA from a 
double stranded template DNA presents an alternative form 
of method for obtaining a single stranded product for 
detection and unlike processes of denaturation of the origi 
nal DNA, it avoids the presence of corresponding amounts 
of the complementary single stranded product Which can 
compete in the detection process. 
Furthermore, the production of an RNA transcript opens 
the Way for ampli?cation of the original DNA sequence 
Without the use of the polymerase chain reaction and Without 
much of the dif?culty normally associated With the 3SR 
ampli?cation technique. In 3SR, a starting RNA is ampli?ed 
by ?rst hybridising to it a DNAprimer constructed to include 
a T7 polymerase promotor sequence. The primer-DNA/ 
template-RNA is extended in its DNA strand by reverse 
transcriptase, the RNA strand is digested by RNase H, and 
the resulting single stranded DNA transcipt is made double 
stranded With reverse transcriptase to provide a template for 
transcription by T7 RNA polymerase to make large number 
of RNA copies. This process is dependent on the construc 
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2 
tion of a DNA primer of the correct sequence doWnstream 
from the T7 promotor sequence. It is further dependent on 
obtaining the nucleic acid sequense of interest in the form of 
RNA. 
According to the present invention hoWever, a nucleic 
acid sequence of interest obtained in the form of double 
stranded DNA can be ampli?ed as multiple single stranded 
RNA copies by synthesising a primer or multiple primer 
sequences of the nucleic acid analogue, Which Will generally 
be much more straightforward than the prior art methods. 
The RNA transcripts produced can be converted to DNA if 
desired. 
Accordingly, the present invention provides a method of 
transcribing RNA from a double stranded DNA template 
comprising forming a complex by hybridising to said tem 
plate at a desired transcription initiation site one or more 
oligo-nucleic acid analogues capable of forming a transcrip 
tion initiation site With said DNA and exposing said complex 
to the action of a DNA dependent RNA polymerase in the 
presence of nucleoside triphosphates. 
Optionally, a pair of said oligo-nucleic acid analogues are 
hybridised to said DNA at spaced locations thereon, on the 
same or different strands thereof 
Preferably, said pair of oligo-nucleic acids are spaced by 
from 0 to 10, more preferably 0 to 5 base pairs of said DNA. 
Preferably also, the or each said oligo-nucleic acid ana 
logue has a length of from 5 to 60 nucleic acid analogue 
units. 
Optionally, a block to transcription is placed at a location 
doWnstream from said desired initiation site so as to produce 
equal length transcripts in said transcription. A suitable Way 
of producing a said block is by hybridising to said DNA an 
oligo-nucleic acid analogue capable of blocking transcrip 
tion. OtherWise, individual transcription events may termi 
nate randomly doWnstreams from the initiation site leading 
to long transcription products of varying length. 
The length of the transcripts can also be controlled by 
cutting the DNA template With a restriction enZyme at a 
speci?c doWnstream location prior to transcription. 
The nucleic acid analogue capable of forming a transcrip 
tion initiation site is preferably a compound that has nucleo 
bases attached to an aminoethylglycine backbone or other 
like backbone including polyamides, polythioanides, 
polysul?namides and polysulfonamides, Which compounds 
We call peptide nucleic acids or PNA. Compounds of this 
kind surprisingly bind strongly and sequence selectively to 
both RNA and DNA. 
The synthesis of this type of compound is fully described 
in WO 92/20703. 
The recognition by PNA of RNA, ssDNA or dsDNA can 
take place in sequences at least 5 bases long. A more 
preferred recognition sequence length is 5—60 base pairs 
long. Sequences betWeen 10 and 20 bases are of particular 
interest since this is the range Within Which unique DNA 
sequences of prokaryotes and eukaryotes are found. 
Sequences of 17—18 bases are of special interest since this is 
the length of unique sequences in the human genome. 
Preferably, the or a nucleic acid analogue used is capable 
of hybridising to a nucleic acid of complementary sequence 
to form a hybrid Which is more stable against denaturation 
by heat than a hybrid betWeen the conventional deoxyribo 
nucleotide corresponding in sequence to said analogue and 
said nucleic acid. 
Preferably, also the or a nucleic acid analogue used is a 
peptide nucleic acid in Which said backbone is a polyamide 
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backbone, each said ligand being bonded directly or indi 
rectly to an aZa nitrogen atom in said backbone, and said 
ligand bearing nitrogen atoms mainly being separated from 
one an other in said backbone by from 4 t o 8 intervening 
atoms. 
Also, it is preferred that the or a nucleic acid analogue 
used is capable of hybridising to a double stranded nucleic 
acid in Which one strand has a sequence complementary to 
said analogue, in such a Way as to displace the other strand 
from said one strand. 
More preferred PNA compounds for use in the invention 
have the formula: 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, naturally 
occurring nucleobases, non-naturally occurring 
nucleobases, aromatic moieties, DNA intercalators, 
nucleobase-binding groups, heterocyclic moieties, and 
reporter ligands; 
each of C1—C” is (CR6R7-)y (preferably CR6R7, 
CHRGCHR7 or CR6R7CH2) Where R6 is hydrogen and R7 is 
selected from the group consisting of the side chains of 
naturally occurring alpha amino acids, or R6 and R7 are 
independently selected from the group consisting of 
hydrogen, (C2—C6)alkyl, aryl, aralkyl, heteroaryl, hydroXy, 
(C1—C6)alkoXy, (C1—C6)alkylthio, NR3R4 and SR5, Where 
R3 and R4 are as de?ned beloW, and R5 is hydrogen, 
(C1—C6)alkyl, hydroXy, alkoXy, or alkylthio-substituted 
(C1—C6)alkyl or R6 and R7 taken together complete an 
alicyclic or heterocyclic system; 
each of D1—D” is (CR6R7)Z (preferably CR6R7, 
CH2CR6R7, or CHR6CHR7) Where R6 and R7 are as de?ned 
above; 
each of y and Z is Zero or an integer from 1 to 10, the sum 
y+Z being at least 2. preferably greater than 2 but not more 
than 10, eg 3, 
in either orientation, Where R3 is as de?ned beloW: 
each of A1—A” and B1—B” are selected such that: 
(a) A is a group of formula (Ila), (11b). (11c) or (11d). and 
B is N or R3N+; or 
(b) A is a group of formula (11d) and B is CH. 
R1 R1 Formula Ha 
I | 
C Y C 
Formula 11b 
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-continued 
flu flu If T? Formula He 
(I: Y (I: N —C— 
R2 R2 
IIU IIU I)? If Formula [Id 
('3 Y (I: C-N — 
R2 R2 
Wherein: 
X is 0.5, Se, NR3’ CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4; 
each of an q is Zero or an integer from 1 to 5, the sum p’q 
being not more than 10 
each of r and s is Zero or an integer from 1 to 5, the sum 
r+s being not more than 10; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl Which may be 
hydroXy- or alkoXy- or alkylthio-substituted, hydroXy, 
alkoXy, alkylthio, amino and halogen; and 
each R3 and R4 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl, hydroXy- or alkoXy 
or alkylthio-substituted (C1—C4)alkyl, hydroXy, alkoXy, 
alkylthio and amino; 
Q is —CO2H, —CONR‘R“, —SO3H or —SO2NR‘R“ or 
an activated derivative of —CO2H or —SO3H; and 
I is NR‘"R““ or —NR‘"C(O)R““, Where R‘, R“, R‘" and 
R““ are independently selected from the group consisting of 
hydrogen, alkyl, amino protecting groups, reporter ligands, 
intercalators, chelators, peptides, proteins, carbohydrates, 
lipids, steroids, nucleosides, nucleotides, nucleotide 
diphosphates, nucleotide triphosphates, oligonucleotides, 
including both oligoribonucleotides and 
oligodoXyribonucleotides, oligonucleosides and soluble and 
non-soluble polymers. “Oligonucleosides” includes nucleo 
bases bonded to ribose and connected via a backbone other 
than the normal phosphate backbone of nucleic acids. 
In the above structures Wherein R‘, R“, R‘" and R““ are 
oligonucleotides or oligonucleosides, such structures can be 
considered chimeric structures betWeen PNA compounds 
and the oligonucleotide or oligonucleoside. 
Generally, at least one of L1—L” Will be naturally occur 
ring nucleobase, a non-naturally occurring nucleobase, a 
DNA intercalator, or a nucleobase binding group. 
Preferred PNA-containing compounds are compounds of 
the formula III, IV or V: 
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F Ir ‘ L Formula III 
0 (CHZ)I O l 
O 
Rh CH2)k N—(CP€) >u_ (CH2)k N_(CH2)m_NH_Ri 
Y \/ NH \/ 
O i [R7 ] P i n [R7 ] p 
F L T L Formula IV 
CH2)! \)CHZ)I 
O NR3 0 NR3 
\( O y 
Rh CH2)k N— (CP€) > _ (CH2)k N _ (CH2)m_ NH_Ri 
Y NH 
' \l/l V 0 R7 P . [R7]. 
h L J Formula V 
0 (C4) /L 3 2 l O 
R \ >/ R3 >/(CHZ)I 
CH ) N O \N 
2 k \ 
Rh V ((3%) (CHZ)m (CH2)m_NH_Ri Y [ 1 NH 
O 7 
i R p n [R7 :l P 
wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, heterocyclic moieties, naturally 
occurring nucleobases, and non-naturally occurring nucleo 
bases; 
each R7 is independently selected from the group con 
sisting of hydrogen and the side chains of naturally occur 
ring alpha arnio acids; 
n is an integer greater than 1, each k, l, and m is, 
independently, Zero or an integer from 1 to 5; 
each p is Zero or 1; 
Rh is OH, NH2 or —NHLysNH2; and R1 is H or COCH3. 
The invention includes a diagnostics method comprising 
carrying out a transcription to produce RNA in accordance 
With the methods of the invention as described above and 
detecting the production of said RNA. Such a method may 
be used to test for the presence or absence in sample DNA 
of a sequence matching that of one or more PNA’s 
employed. 
Suitable, said RNA is captured to a nucleic acid probe of 
complementary sequence and is also bound to a nucleic acid 
probe bearing a detectable label. 
The invention includes a method of nucleic acid ampli 
?cation comprising preparing an RNA transcript from DNA 
by a method in accordance With the above description and in 
such a Way as to produce multiple RNA transcript copies 
from each molecule of DNA template. 
If desired RNA transcribed according to the invention can 
be further ampli?ed using the 3SR technique. 
Afurther subject of the invention is a method of convert 
ing a (starting) nucleic acid into a substrate for transcribing 
RNA including forming a counterstrand of said nucleic acid 
incorporating a speci?c binding sequence, hybridiZing the 
nucleic acid With a nucleic acid analogue, preferably a 
peptide nucleic acid, complementary to the speci?c binding 
sequence, and treating the mixture under conditions adapted 
for transcription under the control of the neWly created 
promotor side. 
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In a speci?c embodiment (described With reference to 
FIG. 6) an RNA to be transcribed is hybridiZed to a 
DNA-oligonucleotide containing at least one nucleic acid 
sequence S1 hybridiZable With said RNA in the region of the 
3‘-end of said RNA. This sequence may have a length of at 
least 15 nucleotides, preferably of about 20 nucleotides. 
Especially preferred the oligonucleotide contains an addi 
tional nucleotide sequence S2 Which can hybridiZe to a site 
Which is located even more at the 3‘-end of the RNA. This 
sequence may be more than 15 nucleotides long, but Will 
preferably be about 40 nucleotides long. In this preferred 
embodiment the 2 sequences of the oligonucleotide are 
connected to each other by a third sequence S3 Which Will 
be the speci?c binding sequence, adapted in sequence for 
speci?c hybridiZation to a nucleic acid analogue used as the 
promotor initiation site. Therefore the third sequence is 
preferably more than 8 nucleotides long preferably about 10 
nucleotides. These nucleotides preferably contain only pyri 
midine bases as nucleobases. Especially preferred the third 
sequence consists of a homopyrimidine stretch. 
The sequences of the starting RNA Which correspond to 
the ?rst and second sequence of the oligonucleotide are 
separated from each other by a sequence of about the same 
length as the third sequence, but not being able to hybridiZe 
to the third sequence. 
For the incorporation of the speci?c binding sequence 
(third sequence) the oligonucleotide is hybridiZed to the 
nucleic acid and eXtended by additional mononucleotides 
using the starting RNA as a template. This is made by the 
reverse transcriptase reaction Which is knoWn in the art. This 
Will leed to a partially double stranded nucleic acid, Which 
contains a stretch being able to hybridiZe With a sequence 
complementary to the speci?c binding sequence. In a further 
step, this hybrid is brought into contact With the nucleic acid 
analogue to hybridiZe With said speci?c binding sequence. 
In case of a homopyrimidine stretch the nucleic acid ana 
logue Will contain the corresponding homopurine stretch. 
5,837,459 
7 
According to the invention this construct Will act as a 
substrate for an RNApolymerase for the production of RNA 
in a transcription reaction. This simple hybridization and 
elongation reaction provides simple access to RNAs, espe 
cially When introduced into an ampli?cation cycle like 
NASBA or 3SR. 
In another embodiment (described With reference to FIG. 
7) a single DNA is used to produce the above mentioned 
double stranded nucleic acid containing the speci?c stretch. 
In this embodiment the single stranded DNA is hybridiZed to 
a DNA-oligonucleotide as described With reference to FIG. 
1. Then reverse transcriptase or DNA dependent DNA 
polymerase is added to extend this oligonucleotide using the 
DNA as a matrix. After denaturation a primer complemen 
tary to the extension product is added and elongated to 
produce an extension product complementary to the ?rst 
extension product. Then the nucleic acid analogue is added 
and transcription is initiated. 
The invention Will be further illustrated by the folloWing 
examples Which make reference to the appended draWings in 
Which: 
FIG. 1 is an autoradiograph of a gel produced in Example 
1. 
FIG. 2 is an autoradiograph of a gel produced in Example 
2. 
FIG. 3 is an autoradiograph of a gel produced in Example 
3. 
FIG. 4 is a model ?gure shoWing construction of the 
different PNA promotors used in the experiments of FIG. 5. 
FIG. 5 is an autoradiograph of an experiment shoWing 
competition betWeen PNA promotors and the lacUV5 pro 
motors. 
FIG. 6 and 7 shoW schemes for preferred embodiments of 
the invention. 
EXAMPLE 1 
Transcription Initiation (1) by single oligo-PNA, (2) by tWo 
oligo-PNA’s Arranged trans and (3) by tWo oligo-PNA’s 
Arranged cis. 
Restriction fragments of three plasmids pT9C, pT9CT9C 
(pUC19 derivatives containing respectively the sequences 
T9C and T9CT9C) and pT9CA9GKS (Bluescript 
KS+derivative containing a T9CA9G sequence) Were iso 
lated by digestion With PvuII and puri?cation on polyacry 
lamide gels resulting in fragments of 338 base pairs (pT9C), 
354 base pairs (pT9CT9C) and 477 base pairs 
(pT9CA9GKS). PNA-DNA complexes Were formed by 
incubating PNA With the DNA fragments in 10 mM Tris 
HCl pH 8.0 and 0.1 mM EDTA in total volume of 15 pl for 
1 hour at 37° C. The reaction mixture Was adjusted to 
contain a ?nal concentration of 40 mM Tris-HCl pH 7.9, 120 
mM KCI, 5 mM MgCI2, 9.1 mM DTT, and 1 mM of ATP, 
CTP, GTP and 0.1 mM of UTP and 5 pCi32P UTP. The PNA 
used Was T9C-lysNH2 in each case. 
The transcriptions Were initiated by addition of 100 nM E 
Coli RNA polymerase holoenZyme (Boehringer Mannheim 
GmbH). The mixtures (total volume of 30 pl) Were incu 
bated at 37° C. for 20 minutes and the RNA produced by 
transcription Was subsequently recovered by ethanol pre 
cipitation. The RNA transcripts Were analysed on 8% dena 
turing polyacrylamide gels, and visualised by autoradiogra 
phy to produce the gel shoWn in FIG. 1. 
As shoWn in the schematics in FIG. 1, the three plasmids 
used provide respectively a single binding site for the PNA 
(mono), a pair of binding sites on the same DNA strand (cis), 
and a pair of binding sites on opposite strands of the DNA 
(trans). 
The lanes of the gel shoW the effect of varying concen 
trations of PNA as follows: 
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Lanes 1, 6 and 11: 0M 
Lanes 2, 7 and 12: 3 nM 
Lanes 3, 8 and 13: 10 nM 
Lanes 4, 9 and 14: 3 pm 
Lanes 5, 10 and 15: 10 pm 
The plasmids used in the lanes Were as folloWs: 
Lanes 1—5: pT9C 
Lanes 6—10: pT9CT9C 
Lanes 7—15: pT9CA9G 
Lane 5 shoWs the production of a single RNA product 
having the siZe expected if transcription proceeds from the 
PNA binding site in the direction shoWn in the correspond 
ing schematic. 
Lane 10 similarly shoWs the production of one RNA 
transcript but transcription is shoWn to be more ef?ciently 
promoted by the presence of tWo oligo PNA’s at the binding 
site arranged in cis. 
Lanes 13 to 15 shoW the production of tWo transcripts of 
the siZes expected if transcription is initiated on each of the 
tWo DNA strands and proceeds from the respective binding 
site to the end of the DNA fragment as illustrated in the 
schematic. 
It is estimated that in those lanes Were transcript RNA is 
seen, from 1 to 5 RNA molecules are being produced per 
DNA template molecule during the 20 minute incubation 
With RNA polymerase. 
EXAMPLE 2 
Transcription Initiation by Single PNA Oligomers of Vary 
ing Base Sequence 
Restriction fragments o f plasmids containing the 
sequences T9C, T9A, an d T9G Were isolated. PNA-DNA 
complexes Were formed With PNA oligomers of correspond 
ing sequence as described in Example 1 and transcription 
Was initiated also as described in Example 1 using E. coli 
polymerase. The resulting transcripts Were visualiZed by 
autoradiography to produce the autoradiography shoWn in 
FIG. 2, demonstrating that transcription is obtainable Which 
ever of the bases A, C and G is present. Lanes 1, 3 and 5 are 
control lanes run Without PNA present during the attempted 
transcription. 
EXAMPLE 3 
Transcription Initiation by Single PNA Oligomers using T7 
and T3 Polyermase 
Using the restriction fragment from the plasmid pT9C and 
the PNA oligomer T9C described in Example 1, transcrip 
tion Was initiated generally as described in Example 1 but 
using separately T3 and T7 polymerase to produce the 
autoradiograph shoWn in FIG. 3. Lanes 1 and 2 are controls 
run in the absence of PNA during attempted transcription 
With T7 (lane 1) and T3 (lande 2) and lanes 5 and 6 shoW the 
effect of the presence of PNA T9C on transcription mediated 
by T7 (lane 5) and T3 (lane 6). 
EXAMPLE 4 
Transciption Initiation using a Second PNA Oligomer 
HybridiZing DoWnstream from the First Transcription Ini 
tiation Site 
Experiments Were undertaken to estimate the strength of 
the PNA-dependent transcription initiation. This Was done 
by having both the strong lacUV5 E. coi promotor and one 
or more PNA targets on the same DNA fragment. These 
constructs and the results of the transcription experiments 
are presented in FIGS. 4 and 5. With the constructs con 
taining one or tWo PNA T1O targets on the template strand 
doWnstream form the lacUV5 promotor (FIG. 4A and B) tWo 
neW transcripts are observed as the PNA concentration is 
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increased. One transcript is assigned to be initiated at the 
PNA target, While the other is assigned to be initiated from 
the UV5 promotor and arrested at the PNA site. A construct 
having tWo PNA T4CT5 targets on the template strand and 
one on the non-template strand only produced transcripts 
assigned to be initiated at the tWo PNA loops and proceeding 
in opposite directions. The intensity of the RNA bands 
decreased at higher PNA concentrations, most likely as a 
consequence of full occupancy of all PNA sites, since an 
occupied PNA site doWnstream form the PNA loop Would 
arrest synthesis from this loop. It is also observed that the 
intensity of the band corresponding to transcription from the 
larger loop is signi?cantly more intensive than that of the 
transcription from the smaller loop, indicating a more effi 
cient transcription from the larger loop. This difference is 
more pronounced than is apparent from the autoradiograph 
taking into account the different siZes of the transcripts. 
The relative positions of hybridiZation are shoWn in FIG. 
5. The sequence to the left indicates the PNA targets 
corresponding to the upper strand from 5 ‘ to 3‘ in the models. 
PNA binding is shoWn by thick bars. The direction of 
transcription is shoWn With the approximated length of the 
RNA product indicated. 
The fragment including a single, a double, or a triple PNA 
binding site together With the lacUV5 promotor Was incu 
bated With the desired amount of PNA for 1 hr at 37° C. The 
transcription reactions Were performed as described above 
except that 20 nM E. coli RNA polymerase Was used. 
The plasmids pT9C, pT9CT9C (pUCI9 derivatives), 
pT9CA9GKS, pT10KS, and pA10KS (Bluescript 
KS+derivatives) Were constructed as described Nielsen, P. 
E., Egholm, M., Berg, R. H. & Buchardt, O. (1993) Anti 
Cancer Drug Des. 8, 53—63; Nielson, P. E. Egholm, M., 
Berg, R. H. & Buchardt, O. (1993) Nucleic Acids Res. 21, 
197—200. The plasmid pUV5 Was constructed by cloning a 
203-bp Eco RI fragment containing the lacUV5 promotor 
(position —150 to +93) into the Eco RI site of pUC18. 
pT9C-UV5 contains three PNA T4CT5 targets each sepa 
rated by 6bp. pA10UV5 contains a single PNA T1O target 
cloned in the BamHI site of pUV5 (A1O on the template 
strand), While pA10A10UV5 contains tWo T1O PNA targets 
separated by a 6-bp linker cloned in the BamHI site of pUV5 
(both A1O on the template strand). The PNA Was synthesiZed 
as described (Egholm, M., Buchardt, O., Nielsen, P. E. & 
Berg, R. H. (1992) J. Am. Chem. Soc. 114, 1895—1897, 
Egholm, M., Buchardt. O., Nielsen, P. E. & Berg, R. H. 
(1992) J. Am. Chem. Soc. 114, 9677—9678). 
Restriction fragments of the plasmids Were isolated by 
digestion With Pvu II and puri?cation on loW-melting aga 
rose gels resulting in fragments of 338 bp (pT9C), 354 bp 
(pT9CT9C), 461 bp (pA10KS and pT10KS), 477 bp 
(pT9CA9GKS), 354 bp (pA10UV5), 370 bp 
(pA10A10UV5), or 386 bp (pT9CUV5). 
In vitro transcription from puri?ed DNA fragments con 
taining a single PNA T1O target (pA10UV5) (A), tWo PNA 
T1O targets in cis (pA10A10TV5) (B) or a triple PNA 
T??CT4 target (one in trans and tWo in cis) (pT9CUV5) (C) 
as Well as a lacUV5 promotor. The concentrations of PNA 
Were as folloWs: lanes 1, 0 nM, lanes 2, 1 nM, lanes 3, 3 nM, 
lanes 4, 10 nM, lanes 5, 30 nM, lanes 6, 0.1 pM, lanes 7, 0.3 
pM. Seventy nanomolar DNA Was used in all experiments. 
Transcription from the UV5 and the PNA promotors are 
marked With arroWs as is transcription arrest. 
The experiments clearly shoW that the transcription ini 
tiated at the ?rst initiation site (UV5) is stopped at the 
second site, alloWing the production of RNA of de?ned 
length. In addition to that, the second site acts as an initiator 
for transcription starting at the second site. 
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In the above description, alkyl moieties, unless otherWise 
speci?ed, preferably contain 1—6, most preferred 1—3 carbon 
atoms. Aromatic moieties, preferably 6—14, most preferred 
6—10 carbon atoms. Both alkyl moieties and aromatic moi 
eties may be substituted or unsubstituted by groups contain 
ing heteroatoms, such as O, N or S. The alkyl moieties can 
be straight-chained or branched. 
Preferred aromatic moieties are phenyl, imidaZolyl, or 
pyridyl. Preferred DNA intercalators include anthraquinolyl, 
psoralyl or ethidium bromide. 
Preferred heterocyclic moieties include piperidinyl, mor 
pholinyl or pyrrolidinyl. 
Preferred reporter ligands include biotinoyl, dioxigenoyl 
or ?uoresceinoyl. 
Preferred chealting moieties include EDTA, NTA or 
bispyridinoyl. 
Preferred aryl groups are phenyl. Preferred aralkyl groups 
are tolyl. Preferred heteroaryl groups include pyrimidinyl. 
Preferred alicyclic or heterocyclic groups for R6 and R7 
include cyclohexenoyl and piperaZinoyl. 
Examples of groups for R‘, R“, R‘" and R““ are the 
folloWing: 
alkyl: methyl; an amino protecting group: 
t-butyloxycarbonyl; a reporter ligand: biotin; an intercalator: 
anthraquinolyl; a chelator: bispyridyl; a peptide: kemptide; 
a protein: alkaline phosphatase; a carbohydrate: sucrose; a 
lipid: cholesterol; a steroid: dioxigenin; a nucleoside: 
adenosin; a nucleotide: adenosine monophosphate; a nucle 
otide diphosphate: adenosine diphosphate; a nucleotide 
triphosphate: adenosine triphosphate; an oligonucleotide: 
A10; a soluable polymer: dextrane; a non-soluable polymer: 
magnetic bead. 
We claim: 
1. Amethod of transcribing RNA, using a double-stranded 
DNA as a template, comprising: 
(a) hybridiZing said double-stranded DNA With a least one 
oligo-nucleic acid analogue to form a hybrid having a 
transcription initiation site, Wherein the hybrid is more 
stable against heat denaturation than a hybrid betWeen 
a conventional deoxyribonucleotide corresponding in 
sequence to said at least one oligo-nucleic acid ana 
logue; 
(b) combining said hybrid With a prokaryotic DNA depen 
dent RNA polymerase and a plurality of nucleoside 
triphosphates; and 
(c) thereafter transcribing said RNA by attaching together 
a plurality of nucleoside triphosphates from step (b), 
using said double-stranded DNA as a template. 
2. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue comprises 5 to 60 base 
pairs. 
3. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue comprises 10 to 20 base 
pairs. 
4. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue comprises 17 to 18 base 
pairs. 
5. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue is a peptide nucleic acid. 
6. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue comprises a plurality of 
nucleotide bases attached to a backbone, said backbone 
comprising a polymer selected from the group consisting of 
polyaminoethylglycine, polyamide, polythioamide, polysul 
?namide and polysulfonamide. 
7. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue comprises a polyamide 
5,837,459 
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backbone and a plurality of ligands, each of said plurality of 
ligands being bonded directly or indirectly to an aZa nitrogen 
atom in said polyamide backbone, Wherein a plurality of the 
ligands bear at least one nitrogen atom and each of said 
plurality of ligands Which bears at least one nitrogen atom is 
separated from another of said plurality of ligands Which 
bears at least one nitrogen atom by from 4 to 8 intervening 
atoms in said polyamide backbone. 
8. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue hybridiZes With one strand 
of said double-stranded DNA having a sequence Which is 
complementary to said at least one oligo-nucleic acid 
analogue, thereby displacing the other strand of said double 
stranded DNA from said one strand of said double-stranded 
DNA. 
9. The method according to claim 1, Wherein said at least 
one oligo-nucleic acid analogue is a compound of formula 1: 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, a 
naturally occurring nucleobase, a non-naturally occur 
ring nucleobase, an aromatic moiety, a DNA 
intercalator, a nucleobase-binding group, a heterocyclic 
moiety, and a reporter ligand; 
each of C1—C” is independently selected from the group 
consisting of (CR6R7)y, (CHR6CHR7)y and 
Wherein R6 is hydrogen and R7 is selected from the 
group consisting of one of the side chains of natu 
rally occurring alpha amino acids, or 
R6 and R7 are independently selected from the group 
consisting of hydrogen, (C2—C6)alkyl, aryl, aralkyl, 
heteroaryl, hydroXy, (C1—C6)alkoXy, (C1—C6) 
alkylthio, NR3R4 and SR5, Wherein R3 and R4 are as 
de?ned beloW, and Wherein R5 is selected from the 
group consisting of hydrogen, (C1—C6)alkyl, 
hydroXy, alkoXy and alkylthio-substituted (C1—C6) 
alkyl, or 
R6 and R7, taken together, form an alicyclic or hetero 
cyclic system; 
each of D1—D” is independently selected from the group 
consisting of (CR6R7)Z, (CH2CR6R7)Z and 
Wherein R6 and R7 are as de?ned above; 
each of y and Z is Zero or an integer from 1 to 10, y+Z 
being at least 2; 
each of G1—G”_1 is independently selected from the group 
consisting of —NR3CO—, —CONR3—, —NR3CS—, 
—CSNR3—, —NR3SO—, —SONR3—, —NR3SO2— 
and —SO2NR3—, Where R3 is as de?ned beloW; 
each of A1—A” and B1—B” are selected such that: 
(a) A is selected from the group consisting of a group of 
formula (Ila), (IIb), (11c) and (11d) , and B is N or R3N+, 
or 
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(b) A is a group of formula (11d) and B is CH; 
R1 R1 Formula Ha 
I | |C Y |C 
R2 R2 
F q 
R1 R1 X Formula IIb 
| | II 
(I: Y (I: C— 
R2 R2 
r s 
Formula IIc 
Formula IId 
Wherein: 
X is selected from the group consisting of O, S, Se, NR3, 
CH2 and C(CH3)2; 
Y is selected from the group consisting of a single bond, 
O, S and NR4; 
each of p and q is Zero or an integer from 1 to 5; 
each of r and s is Zero or an integer from 1 to 5; 
each of R1 and R2 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio, amino and (g) halogen; 
each of R3 and R4 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio and amino; 
Q is selected from the group consisting of —CO2H, 
—CONR‘R“, —SO3H, —SO2NR‘R“, an activated 
derivative of —CO2H and an activated derivative of 
—SO3H; and 
I is NR“‘R““ or —NR“‘C(O)R““, Wherein R‘, R“, R‘" and 
R““ are independently selected from the group consist 
ing of hydrogen, alkyl, an amino protecting group, a 
reporter ligand, an intercalator, a chelator, a peptide, a 
protein, a carbohydrate, a lipid, a steroid, a nucleoside, 
a nucleotide, a nucleotide diphosphate, a nucleotide 
triphosphate, an oligonucleotide, an oligonucleoside 
and a soluble or non-soluble polymer. 
10. A method of transcribing RNA, using a double 
stranded DNA as a template, comprising: 
(a) hybridiZing said double-stranded DNA With a ?rst 
oligo-nucleic acid analogue and a second oligo-nucleic 
acid analogue to form a hybrid, each oligo-nucleic acid 
analogue forming a transcription initiation site With 
said double-stranded DNA, Wherein said ?rst oligo 
nucleic acid analogue is hybridiZed With said double 
stranded DNA at a ?rst location thereon and said 
second oligo-nucleic acid analogue is hybridiZed With 
said double-stranded DNA at a second location thereon, 
said ?rst location being on the same or a different strand 
of said double-stranded DNA, in relation to said second 
location; 
5,837,459 
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(b) combining said hybrid With a DNA dependent RNA 
polymerase and a plurality of nucleoside triphosphates; 
and 
(c) thereafter transcribing said RNA by attaching together 
a plurality of nucleoside triphosphates from step (b), 
using said double-stranded DNA as a template. 
11. The method according to claim 10, Wherein said ?rst 
location is from 0 to 10 base pairs of said double-stranded 
DNA from said second location. 
12. The method according to claim 10, Wherein said ?rst 
location is from 0 to 5 base pairs of said double-stranded 
DNA from said second location. 
13. The method according to claim 9, Wherein 2<y+Z§ 10. 
14. The method according to claim 9, Wherein said at least 
one oligo-nucleic acid analogue is a compound selected 
from the group consisting of formula III, 
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(a) hybridiZing said double-stranded DNA With a least one 
oligo-nucleic acid analogue to form a hybrid having a 
transcription initiation site, Wherein the hybrid is more 
stable against heat denaturation than a hybrid betWeen 
a conventional deoXyribonucleotide corresponding in 
sequence to said at least one oligo-nucleic acid ana 
logue; 
(b) combining said hybrid With a prokaryotic DNA depen 
dent RNA polymerase and a plurality of nucleoside 
triphosphates; 
(c) thereafter transcribing RNA by attaching together a 
plurality of nucleoside triphosphates from step (b), 
using said double-stranded DNA as a template; and 
(d) determining said double-stranded DNA by detecting 
said RNA produced in step 
16. The method according to claim 15, Wherein said 
detecting step (d) comprises hybridiZing said RNA With a 
F If 1 L Formula III 
0 (CHZ)I O ((|:H2)l 
O 
Rh CHZ)k 15%“? >~— (cH2)k N—(CH2)m—NH—Ri 
Y NH \/ 
O i [R7 ] P i n [R7 ] p 
formula IV, 
F L d L Formula IV 
CH2)! \)CHZ)I 
O NR3 0 NR3 
\( O \ 
Rh CH2)k N— (CP€) > _ (CH2)k N _ (CH2)m_ NH_Ri 
Y NH 
' \l/l \/ O [R71 
L .4 P 
and formula V 
r L Formula V 
0 (C4) /L 3 2 l O 
R \ >/ R3 >/(CHZ)I 
CHz)k N (CH) O\ \N 
Rh V \2 (CHM <cH2>m—NH—Ri Y [ 1 NH 
O 7 
i R p n [R7 :l P 
Wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, a heterocyclic moiety, at least 
one naturally occurring nucleobase, and at least one 
non-naturally occurring nucleobase; 
each R7 is independently selected from the group con 
sisting of hydrogen and one of the side chains of 
naturally occurring alpha amino acids; 
n is an integer greater than 1, 
each of k, l, and m is, independently, Zero or an integer 
from 1 to 5; 
each p is Zero or 1; 
Rh is one of OH, NH2 and —NHLysNH2; and 
Ri is H or COCH3. 
15. A method of detecting a double-stranded DNA, com 
prising: 
65 
nucleic acid probe having a sequence Which is complemen 
tary to said RNA. 
17. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue comprises 5 to 60 base 
pairs. 
18. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue comprises 10 to 20 
base pairs. 
19. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue comprises 17 to 18 
base pairs. 
20. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue is a peptide nucleic 
acid. 
21. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue comprises a plurality 
5,837,459 
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of nucleotide bases attached to a backbone, said backbone 
comprising a polymer selected from the group consisting of 
polyaminoethylglycine, polyamide, polythioamide, polysul 
?namide and polysulfonamide. 
22. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue comprises a polyamide 
backbone and a plurality of ligands, each of said plurality of 
ligands being bonded directly or indirectly to an aZa nitrogen 
atom in said polyamide backbone, Wherein each ligand 
binding aZa nitrogen atom is separated from an adjacent 
ligand-binding aZa nitrogen atom by from 4 to 8 intervening 
atoms in said polyamide backbone. 
23. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue hybridiZes With one 
strand of said double-stranded DNA having a sequence 
Which is complementary to said at least one oligo-nucleic 
acid analogue, thereby displacing the other strand of said 
double-stranded DNA from said one strand of said double 
stranded DNA. 
24. The method according to claim 15, Wherein said at 
least one oligo-nucleic acid analogue is a compound of 
formula 1: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, a 
naturally occurring nucleobase, a non-naturally occur 
ring nucleobase, an aromatic moiety, a DNA 
intercalator, a nucleobase-binding group, a heterocyclic 
moiety, and a reporter ligand; 
each of C1—C” is independently selected from the group 
consisting of (CR6R7)y, (CHR6CHR7)y and (CR6R7CH2)y 
Wherein R6 is hydrogen and R7 is selected from the 
group consisting of one of the side chains of natu 
rally occurring alpha amino acids, or 
R6 and R7 are independently selected from the group 
consisting of hydrogen, (C2—C6)alkyl, aryl, aralkyl, 
heteroaryl, hydroXy, (C1—C6)alkoXy, (C1—C6) 
alkylthio, NR3R4 and SR5, Wherein R3 and R4 are as 
de?ned beloW, and Wherein R5 is selected from the 
group consisting of hydrogen, (C1—C6)alkyl, 
hydroXy, alkoXy and alkylthio-substituted (C1—C6) 
alkyl, or 
R6 and R7, taken together, form an alicyclic or hetero 
cyclic system; 
each of D1—D” is independently selected from the group 
consisting of (CR6R7)Z, (CH2CR6R7)Z and 
(CHR6CHR7 Z 
Wherein R6 and R7 are as de?ned above; 
each of y and Z is Zero or an integer from 1 to 10, y+Z 
being at least 2; 
each of G1—G”_1 is independently selected from the group 
consisting of —NR3CO—, —CONR3—, —NR3CS—, 
—CSNR3—, —NR3SO—, —SONR3—, —NR3SO2— 
and —SO2NR3—, Where R3 is as de?ned beloW; 
each of A1—A” and B1—B” are selected such that: 
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(a) A is selected from the group consisting of a group of 
formula (Ila), (11b), (11c) and (IId), and B is N or R3N+, 
or 
(b) A is a group of formula (11d) and B is CH; 
R1 R1 Formula Ha 
I | 
‘f Y ‘f 
R2 R2 
F q 
R1 R1 X Formula IIb 
| | II 
(I: Y (I: C 
R2 R2 
r s 
Formula IIc 
Formula IId 
Wherein: 
X is selected from the group consisting of O, S, Se, NR3, 
CH2 and C(CH3)2; 
Y is selected from the group consisting of a single bond, 
O, S and NR4; 
each of p and q is Zero or an integer from 1 to 5; 
each of r and s is Zero or an integer from 1 to 5; 
each of R1 and R2 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio, amino and (g) halogen; 
each of R3 and R4 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio and amino; 
Q is selected from the group consisting of —CO2H, 
—CONR‘R“, —SO3H, —SO2NR‘R“, an activated 
derivative of —CO2H and an activated derivative of 
—SO3H; and 
I is NR“‘R“ or —NR“‘ C(O)R““, Wherein R‘, R“, R‘" and 
R““ are independently selected from the group consist 
ing of hydrogen, alkyl, an amino protecting group, a 
reporter ligand, an intercalator, a chelator, a peptide, a 
protein, a carbohydrate, a lipid, a steroid, a nucleoside, 
a nucleotide, a nucleotide diphosphate, a nucleotide 
triphosphate, an oligonucleotide, an oligonucleoside 
and a soluble or non-soluble polymer. 
25. The method according to claim 16, Wherein said 
nucleic acid probe comprises a detectable label. 
26. The method according to claim 24, Wherein 2<y+Z 
E10. 
27. The method according to claim 24, Wherein said at 
least one oligo-nucleic acid analogue is a compound selected 
from the group consisting of formula III, 
5,837,459 
wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, a heterocyclic moiety, at least 
one naturally occurring nucleobase, and at least one 
non-naturally occurring nucleobase; 
each R7 is independently selected from the group con 
sisting of hydrogen and one of the side chains of 
naturally occurring alpha amino acids; 
n is an integer greater than 1, 
each of k, l, and m is, independently, Zero or an integer 
from 1 to 5; 
each p is Zero or 1; 
R]1 is one of OH, NH2 and —NHLysNH2; and 
Ri is H or COCH3. 
28. A method of amplifying RNA, comprising: 
(a) hybridizing a double-stranded DNA With at least one 
oligo-nucleic acid analogue forming a transcription 
initiation site With said double-stranded DNA, to form 
a hybrid; 
(b) combining said hybrid formed in step (a) With a DNA 
dependent RNA polymerase and a plurality of nucleo 
side triphosphates; 
(c) thereafter transcribing RNA by attaching together a 
plurality of nucleoside triphosphates from step (b), 
using said double-stranded DNA as a template; 
(d) hybridiZing said RNA produced in step (c) With a 
nucleic acid primer, to form a hybrid; 
(e) extending said nucleic acid primer of said hybrid 
formed in step (d), using said RNA as a template, to 
produce an eXtension product; and 
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F Ir ‘ L Formula III 
0 (CHZ)I O ((|:H2)l 
O 
Rh CHZ)k 18%“? >~— (cH2)k N—(CH2)m—NH—Ri 
Y \/ NH \/ 
O i [R7 ] P i n [R7 ] p 
formula IV, 
F L d L Formula IV 
CH2); CH2) 
0 NR3 0 NR3 
\( O y 
Rh CH2)‘ “(CH9 >~—<<:H2>k N—<CHZ>m—NH—Ri 
Y NH 
' l l O [R71 
L .4 P 
and formula V 
r L Formula V 
0 (C4) L 3 2 l 
R \ l’ R\ <CH2>1 
CH2)" N (CH) O\ N 
Rh V \2 (CHM (CH2)m_NH_Ri Y [ 1 NH 
O R7 
i P n [R7 :l P 
(f) transcribing RNA, using the eXtension product pro 
duced in step (e) as a template. 
29. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue comprises 5 to 60 base 
pairs. 
30. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue comprises 10 to 20 
base pairs. 
31. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue comprises 17 to 18 
base pairs. 
32. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue is a peptide nucleic 
acid. 
33. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue comprises a plurality 
of nucleotide bases attached to a backbone, said backbone 
comprising a polymer selected from the group consisting of 
polyaminoethylglycine, polyamide, polythioamide, polysul 
?namide and polysulfonamide. 
34. The method according to claim 28, Wherein said at 
least one oligo-nucleic acid analogue comprises a polyamide 
backbone and a plurality of ligands, each of said plurality of 
ligands being bonded directly or indirectly to an aZa nitrogen 
atom in said polyamide backbone, Wherein each ligand 
binding aZa nitrogen atom is separated from an adjacent 
ligand-binding aZa nitrogen atom by from 4 to 8 intervening 
atoms in said polyamide backbone. 
35. The method according to claim 28, Wherein, in step 
(a), said at least one oligo-nucleic acid analogue hybridiZes 
With one strand of said double-stranded DNA having a 
sequence Which is complementary to said at least one 
oligo-nucleic acid analogue, thereby displacing the other 
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strand of said double-stranded DNA from said one strand of 
said double-stranded DNA. 
36. The method according to claim 28, wherein said at 
least one oligo-nucleic acid analogue is a compound of 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, a 
naturally occurring nucleobase, a non-naturally occur 
ring nucleobase, an aromatic moiety, a DNA 
intercalator, a nucleobase-binding group, a heterocyclic 
moiety, and a reporter ligand; 
each of C1—C” is independently selected from the group 
consisting of (CR6R7)y, (CHR6CHR7)y and (CR6R7CH2)y 
Wherein R6 is hydrogen and R7 is selected from the 
group consisting of one of the side chains of natu 
rally occurring alpha amino acids, or 
R6 and R7 are independently selected from the group 
consisting of hydrogen, (C2—C6)alkyl, aryl, aralkyl, 
heteroaryl, hydroXy, (C1—C6)alkoXy, (C1—C6) 
alkylthio, NR3R4 and SR5, Wherein R3 and R4 are as 
de?ned beloW, and Wherein R5 is selected from the 
group consisting of hydrogen, (C1—C6)alkyl, 
hydroXy, alkoXy and alkylthio-substituted (C1—C6) 
alkyl, or 
R6 and R7, taken together, form an alicyclic or hetero 
cyclic system; 
each of D1—D” is independently selected from the group 
consisting of (CR6R7)Z, (CH2CR6R7)Z and 
(CHR6CHR7 Z 
Wherein R6 and R7 are as de?ned above; 
each of y and Z is Zero or an integer from 1 to 10, y+Z 
being at least 2; 
each of G1—G"_1 is independently selected from the group 
consisting of —NR3CO—, —CONR3—, —NR3CS—, 
—CSNR3—, —NR3SO—, —SONR3—, —NR3SO2— 
and —SO2NR3—, Where R3 is as de?ned beloW; 
each of A1—A” and B1—B” are selected such that: 
(a) A is selected from the group consisting of a group of 
formula (Ila), (IIb), (11c) and (IId), and B is N or R3N+, 
or 
(b) A is a group of formula (IId) and B is CH; 
Formula IIa 
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R1 R1 X Formula IIb 
| | II 
(I: Y (I: C— 
r s 
R1 R1 R3 0 Formula IIc 
| | | II (I: Y (I: N—C— 
R2 R2 
r s 
Formula IId 
X is selected from the group consisting of O, S, Se, NR3, 
CH2 and C(CH3)2; 
Y is selected from the group consisting of a single bond, 
O, S and NR4; 
each of p and q is Zero or an integer from 1 to 5; 
each of r and s is Zero or an integer from 1 to 5; 
each of R1 and R2 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoxy, (e) alkylthio, amino and (g) halogen; 
each of R3 and R4 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio and amino; 
Q is selected from the group consisting of —CO2H, 
—CONR‘R“, —SO3H, —SO2NR‘R“, an activated 
derivative of —CO2H and an activated derivative of 
—SO3H; and 
I is NR“‘R““ or —NR“‘C (O)R““, Wherein R‘, R“, R“‘ and 
R““ are independently selected from the group consist 
ing of hydrogen, alkyl, an amino protecting group, a 
reporter ligand, an intercalator, a chelator, a peptide, a 
protein, a carbohydrate, a lipid, a steroid, a nucleoside, 
a nucleotide, a nucleotide diphosphate, a nucleotide 
triphosphate, an oligonucleotide, an oligonucleoside 
and a soluble or non-soluble polymer. 
37. The method according to claim 36, Wherein 2<y+ 
Z i 10. 
38. The method according to claim 36, Wherein said at 
least one oligo-nucleic acid analogue is a compound selected 
from the group consisting of formula III, 
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and formula V 
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wherein 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, a heterocyclic moiety, at least 
one naturally occurring nucleobase, and at least one 
non-naturally occurring nucleobase; 
each R7 is independently selected from the group con 
sisting of hydrogen and one of the side chains of 
naturally occurring alpha amino acids; 
n is an integer greater than 1, 
each of k, l, and m is, independently, Zero or an integer 
from 1 to 5; 
each p is Zero or 1; 
Rh is one of OH, NH2 and —NHLysNH2; and 
Ri is H or COCH3. 
39. A method of converting a starting nucleic acid into a 
double-stranded DNA template for transcribing RNA, com 
prising: 
(a) hybridizing said starting nucleic acid With ?rst DNA 
oligonucleotide comprising a speci?c binding 
sequence, to form a ?rst hybrid; 
(b) extending said DNA oligonucleotide of said ?rst 
hybrid, using said starting nucleic acid as a template, to 
form a ?rst extension hybrid comprising said starting 
nucleic acid and a ?rst extension product; 
(c) denaturing said ?rst extension hybrid formed in (b); 
(d) hybridiZing said ?rst extension product With a second 
DNA oligonucleotide comprising a sequence Which is 
complementary to a portion of said ?rst extension 
product; 
(e) extending said second DNA oligonucleotide using said 
?rst extension product as a template to form a second 
extension hybrid comprising said ?rst extension prod 
uct and said second extension product; 
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(f) thereafter hybridiZing said second extension hybrid 
With an oligo-nucleic acid analogue comprising a 
sequence Which is complementary to said speci?c 
binding sequence, to form a double-stranded DNA 
template for transcribing RNA. 
40. The method according to claim 39, Wherein said 
starting nucleic acid is RNA. 
41. The method according to claim 39, Wherein said 
starting nucleic acid is DNA. 
42. The method according to claim 39, Wherein said ?rst 
DNA oligonucleotide further comprises a nucleic acid 
sequence S1 Which hybridiZes With said starting nucleic acid 
toWard the 3‘-end of said starting nucleic acid. 
43. The method according to claim 39, Wherein said 
speci?c binding sequence comprises more than 8 nucle 
otides. 
44. The method according to claim 39, Wherein said 
speci?c binding sequence consists of a plurality of pyrimi 
dine bases. 
45. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue comprises 5 to 60 base pairs. 
46. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue comprises 10 to 20 base pairs. 
47. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue comprises 17 to 18 base pairs. 
48. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue is a peptide nucleic acid. 
49. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue comprises a plurality of nucle 
otide bases attached to a backbone, said backbone compris 
ing a polymer selected from the group consisting of 
polyaminoethylglycine, polyamide, polythioamide, polysul 
?namide and polysulfonamide. 
50. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue comprises a polyamide back 
5,837,459 
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bone and a plurality of ligands, each of said plurality of 
ligands being bonded directly or indirectly to an aZa nitrogen 
atom in said polyamide backbone, Wherein each ligand 
binding aZa nitrogen atom is separated from an adjacent 
ligand-binding aZa nitrogen atom by from 4 to 8 intervening 
atoms in said polyamide backbone. 
51. The method according to claim 39, Wherein said 
oligo-nucleic acid analogue is a compound of formula 1: 
L" Formula 1 | | | 
A1 A2 An 
2 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, a 
naturally occurring nucleobase, a non-naturally occur 
ring nucleobase, an aromatic moiety, a DNA 
intercalator, a nucleobase-binding group, a heterocyclic 
moiety, and a reporter ligand; 
each of C1—C” is independently selected from the group 
consisting of (CR6R7)y, (CHR6CHR7)y and 
(CR6R7CH )‘v 
Wherein R is hydrogen and R7 is selected from the 
group consisting of one of the side chains of natu 
rally occurring alpha amino acids, or 
R6 and R7 are independently selected from the group 
consisting of hydrogen, (C2—C6)alkyl, aryl, aralkyl, 
heteroaryl, hydroXy, (C1—C6)alkoXy, (C1—C6) 
alkylthio, NR3R4 and SR5, Wherein R3 and R4 are as 
de?ned beloW, and Wherein R5 is selected from the 
group consisting of hydrogen, (C1—C6)alkyl, 
hydroXy, alkoXy and alkylthio-substituted (C1—C6) 
alkyl, or 
R6 and R7, taken together, form an alicyclic or hetero 
cyclic system; 
each of D1—D” is independently selected from the group 
consisting of (CR6R7)Z, (CH2CR6R7)Z and 
(CHR6CHR7 Z 
Wherein R6 and R7 are as de?ned above; 
each of y and Z is Zero or an integer from 1 to 10, y+Z 
being at least 2; 
each of G‘lG”1 is independently selected from the group 
consisting of —NR3CO—, —CONR3—, —NR3CS—, 
—CSNR3—, —NR3SO—, —SONR3—, —NR3SO2— 
and —SO2NR3—, Where R3 is as de?ned beloW; 
each of A1—A” and B1—B” are selected such that: 
(a) A is selected from the group consisting of a group of 
formula (Ila) , (IIb) , (IIc) and (IId), and B is N or R3N+, 
or 
(b) A is a group of formula (IId) and B is CH; 
Formula IIa 
Formula IIb 
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-continued 
R1 R1 R3 0 Formula IIc 
| | | II (I: Y (I: N—C— 
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Wherein: 
X is selected from the group consisting of O, S, Se, NR3, 
CH2 and C(CH3)2; 
Y is selected from the group consisting of a single bond, 
O, S and NR4; 
each of p and q is Zero or an integer from 1 to 5; 
each of r and s is Zero or an integer from 1 to 5; 
each of R1 and R2 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio, amino and (g) halogen; 
each of R3 and R4 is independently selected from the 
group consisting of (a) hydrogen, (b) (C1—C4)alkyl 
Which is unsubstituted or substituted by one of 
hydroXy-, alkoXy- and alkylthio-, (c) hydroXy, (d) 
alkoXy, (e) alkylthio and amino; 
Q is selected from the group consisting of —CO2H, 
—CONR‘R“, —SO3H, —SO2NR‘R“, an activated 
derivative of —CO2H and an activated derivative of 
—SO3H; and 
I is NR“‘R““ or —NR“‘C(O)R““, Wherein R‘, R“, R‘" and 
R““ are independently selected from the group consist 
ing of hydrogen, alkyl, an amino protecting group, a 
reporter ligand, an intercalator, a chelator, a peptide, a 
protein, a carbohydrate, a lipid, a steroid, a nucleoside, 
a nucleotide, a nucleotide diphosphate, a nucleotide 
triphosphate, an oligonucleotide, an oligonucleoside 
and a soluble or non-soluble polymer. 
52. The method according to claim 42, Wherein said 
nucleic acid sequence S1 comprises at least 15 nucleotides. 
53. The method according to claim 42, Wherein said 
nucleic acid sequence S1 comprises about 20 nucleotides. 
54. The method according to claim 42, Wherein said ?rst 
DNA oligonucleotide further comprises a nucleic acid 
sequence S2 Which hybridiZes With said starting nucleic acid 
further upstream toWard the 5‘-end of said starting nucleic 
acid, compared to said nucleic acid sequence S1, Wherein 
said speci?c binding sequence is located betWeen said 
nucleic acid sequence S1 and said nucleic acid sequence S2. 
55. The method according to claim 54, Wherein said 
nucleic acid sequence S2 comprises more than 15 nucle 
otides. 
56. The method according to claim 54, Wherein said 
nucleic acid sequence S2 comprises about 40 nucleotides. 
57. The method according to claim 43, Wherein said 
speci?c binding sequence comprises about 10 nucleotides. 
58. The method according to claim 51, Wherein 2<y+ 
Z2 10. 
59. The method according to claim 51, Wherein said at 
least one oligo-nucleic acid analogue is a compound selected 
from the group consisting of formula III, 
5,837,459 
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wherein 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, a heterocyclic moiety, at least 
one naturally occurring nucleobase, and at least one 
non-naturally occurring nucleobase; 
each R7 is independently selected from the group con 
sisting of hydrogen and one of the side chains of 
naturally occurring alpha amino acids; 
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Formula III 
Formula IV 
Formula V 
n is an integer greater than 1, 
each of k, l, and m is, independently, Zero or an integer 
from 1 to 5; 
each p is Zero or 1; 
Rh is one of OH, NH2 and —NHLysNH2; and 
Ri is H or COCH3. 
* * * * * 
